CA2539837C - Identification of tumour-associated cell surface antigens for diagnosis and therapy - Google Patents

Identification of tumour-associated cell surface antigens for diagnosis and therapy Download PDF

Info

Publication number
CA2539837C
CA2539837C CA2539837A CA2539837A CA2539837C CA 2539837 C CA2539837 C CA 2539837C CA 2539837 A CA2539837 A CA 2539837A CA 2539837 A CA2539837 A CA 2539837A CA 2539837 C CA2539837 C CA 2539837C
Authority
CA
Canada
Prior art keywords
tumor
nucleic acid
associated antigen
cancer
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2539837A
Other languages
English (en)
French (fr)
Other versions
CA2539837A1 (en
Inventor
Oezlem Tuereci
Ugur Sahin
Gerd Helftenbein
Volker Schlueter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNTech SE
Original Assignee
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals GmbH filed Critical Ganymed Pharmaceuticals GmbH
Priority to CA2814269A priority Critical patent/CA2814269C/en
Priority to CA2984653A priority patent/CA2984653C/en
Publication of CA2539837A1 publication Critical patent/CA2539837A1/en
Application granted granted Critical
Publication of CA2539837C publication Critical patent/CA2539837C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
CA2539837A 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy Expired - Lifetime CA2539837C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2814269A CA2814269C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2984653A CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10344799A DE10344799A1 (de) 2003-09-26 2003-09-26 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE10344799.7 2003-09-26
PCT/EP2004/010697 WO2005030250A2 (de) 2003-09-26 2004-09-23 Identifizierung von tumorassoziierten zelloberflächen-antigenen für die diagnose und therapie

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA2984653A Division CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2814269A Division CA2814269C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Publications (2)

Publication Number Publication Date
CA2539837A1 CA2539837A1 (en) 2005-04-07
CA2539837C true CA2539837C (en) 2017-12-19

Family

ID=34306102

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2539837A Expired - Lifetime CA2539837C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2814269A Expired - Lifetime CA2814269C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2984653A Expired - Lifetime CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA3096188A Expired - Lifetime CA3096188C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA2814269A Expired - Lifetime CA2814269C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA2984653A Expired - Lifetime CA2984653C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy
CA3096188A Expired - Lifetime CA3096188C (en) 2003-09-26 2004-09-23 Identification of tumour-associated cell surface antigens for diagnosis and therapy

Country Status (8)

Country Link
US (6) US7875424B2 (enExample)
EP (22) EP2266617A3 (enExample)
JP (5) JP5144933B2 (enExample)
AU (1) AU2004275500B2 (enExample)
CA (4) CA2539837C (enExample)
DE (1) DE10344799A1 (enExample)
ES (1) ES2634705T3 (enExample)
WO (1) WO2005030250A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CN1886506B (zh) * 2003-09-29 2012-05-30 中外制药株式会社 在nk细胞中表达的蛋白质
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1907580A2 (en) * 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8404810B2 (en) * 2006-02-17 2013-03-26 Five Prime Therapeutics, Inc. Compositions and methods of use for modulators of polypeptides and polynucleotides in treating breast cancer and melanoma
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2010050190A1 (ja) 2008-10-27 2010-05-06 北海道公立大学法人札幌医科大学 がん幹細胞分子マーカー
US20130017546A1 (en) 2009-10-26 2013-01-17 Externautics S.P.A. Breast Tumor Markers and Methods of Use Thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
WO2011051278A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051276A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Colon and rectal tumor markers and methods of use thereof
US10288617B2 (en) 2009-10-26 2019-05-14 Externautics Spa Ovary tumor markers and methods of use thereof
FR2973380B1 (fr) * 2011-04-01 2018-02-09 C.Ris Pharma Peptides isoles et purifies a partir de testicules de roussette
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
TW201302800A (zh) * 2011-06-10 2013-01-16 腫瘤療法 科學股份有限公司 Ｓｅｍａ５ｂ胜肽及含其之疫苗
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US20200040103A1 (en) * 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
CA3242459A1 (en) * 2021-12-27 2023-07-06 Memorial Sloan-Kettering Cancer Center Tumor mhc class i expression is associated with interleukin-2 response in melanoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
WO1995004068A1 (en) * 1993-07-29 1995-02-09 Isis Pharmaceuticals, Inc. Oligomers for modulating human immunodeficiency virus
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
SE508004C2 (sv) 1996-08-07 1998-08-10 Intermec Ptc Ab Arrangemang för automatisk inställning av printrar samt material därtill
CA2281059A1 (en) * 1997-02-24 1998-08-27 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998055508A2 (en) * 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US6312922B1 (en) * 1998-02-09 2001-11-06 Genset Complementary DNAs
CA2354369A1 (en) * 1998-12-22 2000-06-29 Genset S.A. Complementary dna's encoding proteins with signal peptides
CA2368098A1 (en) * 1999-06-25 2001-01-04 Genset S.A. Complementary dna's encoding proteins with signal peptides
WO2001054472A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001077292A2 (en) * 2000-04-07 2001-10-18 Senomyx, Inc. Novel signal transduction molecules
EP1297128A2 (en) * 2000-05-18 2003-04-02 Incyte Genomics, Inc. G-protein coupled receptors
JP2002112793A (ja) * 2000-08-04 2002-04-16 Japan Science & Technology Corp 新規ｇ蛋白質共役受容体
AU2001288237A1 (en) * 2000-08-07 2002-02-18 Curagen Corporation Proteins and nucleic acids encoding g-protein coupled receptors
AU2001293854A1 (en) * 2000-10-04 2002-04-15 Bayer Aktiengesellschaft Regulation of human gpcr-like protein
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2460621A1 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2005514051A (ja) * 2001-12-21 2005-05-19 ジーン ロジック インコーポレイテッド 胃癌における遺伝子発現プロファイル
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
US20030170639A1 (en) * 2002-03-11 2003-09-11 Youmin Shu Liver transmembrane protein gene
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7081340B2 (en) * 2002-03-13 2006-07-25 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003263660A1 (en) * 2003-08-29 2005-03-16 Pantarhei Bioscience B.V. Prenatal diagnosis of down syndrome by detection of fetal rna markers in maternal blood
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

Also Published As

Publication number Publication date
EP1664113A2 (de) 2006-06-07
WO2005030250A3 (de) 2005-08-18
US9267177B2 (en) 2016-02-23
EP2267013A2 (de) 2010-12-29
CA2814269C (en) 2017-12-19
EP2332979A3 (de) 2011-09-14
EP2332980A3 (de) 2012-02-01
EP2266613A3 (de) 2011-08-03
EP2267014A3 (de) 2012-01-11
EP2266611A2 (de) 2010-12-29
JP5639989B2 (ja) 2014-12-10
EP2266616A2 (de) 2010-12-29
EP2266614A2 (de) 2010-12-29
EP2266611A3 (de) 2011-08-03
CA3096188A1 (en) 2005-04-07
EP2267013A3 (de) 2011-06-08
EP2267012A3 (de) 2011-05-04
EP2266612A3 (de) 2011-11-23
US20160053332A1 (en) 2016-02-25
EP1664113B1 (de) 2018-01-03
JP5804519B2 (ja) 2015-11-04
EP2332983A3 (de) 2012-02-01
EP2266608B1 (de) 2016-05-25
CA2814269A1 (en) 2005-04-07
US9910043B2 (en) 2018-03-06
US9733251B2 (en) 2017-08-15
AU2004275500B2 (en) 2011-07-14
EP2266612A2 (de) 2010-12-29
US20110135640A1 (en) 2011-06-09
JP2016199548A (ja) 2016-12-01
EP2266613B1 (de) 2016-12-14
EP2266614A3 (de) 2012-01-11
CA3096188C (en) 2022-06-07
EP2266615A2 (de) 2010-12-29
EP2267012B1 (de) 2017-04-26
EP2295077A3 (de) 2011-08-10
EP2272534A2 (de) 2011-01-12
EP2332983A2 (de) 2011-06-15
US20130280166A1 (en) 2013-10-24
ES2634705T3 (es) 2017-09-28
EP2295077A2 (de) 2011-03-16
US20160195539A1 (en) 2016-07-07
EP2272534A3 (de) 2011-06-15
CA2984653A1 (en) 2005-04-07
CA2539837A1 (en) 2005-04-07
EP2266612B1 (de) 2018-01-03
EP2332981A2 (de) 2011-06-15
EP2266609A2 (de) 2010-12-29
EP2332981A3 (de) 2012-02-01
US20080166340A1 (en) 2008-07-10
EP2266617A2 (de) 2010-12-29
EP2266618A2 (de) 2010-12-29
CA2984653C (en) 2020-12-15
JP5144933B2 (ja) 2013-02-13
EP2266608A2 (de) 2010-12-29
EP2267012A2 (de) 2010-12-29
JP2014221760A (ja) 2014-11-27
EP2267013B1 (de) 2015-11-11
EP2266610A3 (de) 2012-01-25
EP2332979A2 (de) 2011-06-15
EP2266616A3 (de) 2011-09-14
JP5969538B2 (ja) 2016-08-17
JP2013063975A (ja) 2013-04-11
DE10344799A1 (de) 2005-04-14
US9139880B2 (en) 2015-09-22
US20150376718A1 (en) 2015-12-31
EP2266615A3 (de) 2011-09-21
WO2005030250A2 (de) 2005-04-07
EP2267014A2 (de) 2010-12-29
EP2266610A2 (de) 2010-12-29
US7875424B2 (en) 2011-01-25
AU2004275500A1 (en) 2005-04-07
EP2266617A3 (de) 2012-01-25
EP2266609A3 (de) 2012-02-01
EP2266618A3 (de) 2011-06-22
EP2332980A2 (de) 2011-06-15
EP2267011A2 (de) 2010-12-29
JP6196350B2 (ja) 2017-09-13
JP2007506417A (ja) 2007-03-22
EP2266613A2 (de) 2010-12-29
JP2012110324A (ja) 2012-06-14
EP2266608A3 (de) 2012-01-25
EP2267011A3 (de) 2011-05-18

Similar Documents

Publication Publication Date Title
US9910043B2 (en) Identification of tumor-associated cell surface antigens for diagnosis and therapy
US10036753B2 (en) Identification of surface-associated antigens for tumor diagnosis and therapy
AU2012233057B2 (en) Identification of tumour-associated cell surface antigens for diagnosis and therapy
AU2015201738B2 (en) Identification of tumour-associated cell surface antigens for diagnosis and therapy

Legal Events

Date Code Title Description
EEER Examination request